Technical Articles

Ovarian cancer, as the most lethal gynecological malignancy, faces significant challenges in early diagnosis. About 75% of patients are diagnosed at advanced stages, with a five-year survival rate of less than 30%. In this clinical dilemma, the discovery of human epididymal protein 4 (HE4) has brought new hope for early screening and precise diagnosis and treatment of ovarian cancer.